Chlamydia Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Sexually Transmitted Diseases Globally
- Rising Demand for Screening of the Disease
Challenges
- Social Stigma Associated with STIs
Chlamydia Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.6% |
|
Base Year Market Size (2024) |
USD 3.33 billion |
|
Forecast Year Market Size (2037) |
USD 9.73 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of chlamydia is assessed at USD 3.57 billion.
Chlamydia Market size was valued at USD 3.33 billion in 2024 and is expected to reach USD 9.73 billion by 2037, expanding at around 8.6% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is predicted to hold largest revenue share by 2037, on account of growing demand for medical screening and burgeoning need for raising awareness about STIs.
The major players in the market are Pfizer, Inc., GlaxoSmithKline Plc, AstraZeneca plc, Gilead Sciences Inc., Sanofi Group, and others.
